ForSight Robotics raises $125M Series B to advance AI-powered eye surgery system
Israeli medtech firm’s ORYOM platform aims to expand access to precision eye care globally.
Israeli eye surgery robotics company ForSight Robotics has raised $125 million in a Series B round led by Eclipse. The funding will be used to advance development of the company’s ORYOM platform, a robotic system designed to perform cataract surgery and treat other common eye diseases. The system aims to deliver more precise procedures, expand access to quality care, and reduce the physical burden on surgeons. ForSight’s first human clinical trials are expected to begin this year.
Full list of Israeli high-tech funding rounds in 2025
Founded in 2020 by Prof. Moshe Shoham, Dr. Daniel Glozman, and Dr. Joseph Nathan, ForSight is currently headquartered in Yokneam Illit and will soon relocate to Caesarea. The company has raised $195 million to date and employs 110 people in Israel.
In addition to Eclipse, the round included investment from a strategic corporate partner, Dr. Fred Moll, who is widely regarded as the “father of surgical robotics,” India’s Adani Group, Reiya Ventures, and other existing backers. The company has already conducted hundreds of successful preclinical procedures in animal trials and will soon begin robotic cataract surgeries in humans.
“We finalized the round while missiles were flying into Israel. Twenty percent of our team is in the reserves, we support them and their families deeply,” Natahn told Calcalist. “We’ve faced COVID, economic crises, and now war. Still, we secured backing from some of Silicon Valley’s largest funds in both our Series A and B. Our uniqueness is stronger than the challenges around us.”
Dr. Nathan emphasized that the round represents a strong vote of confidence from a key industry player “A strategic company in our space invested a substantial amount, but entered only as a financial partner, I’m not tied to them strategically. All funds go to the company and are not contingent on milestones.”
The new capital will help ForSight move through regulatory pathways, launch U.S. operations, and prepare for commercialization. “I believe we’ll reach the market in the coming years once we secure all FDA approvals,” said Nathan.
“There’s no existing robotic solution in ophthalmology. We are reengineering eye surgery. Instead of a surgeon manually operating tools, they’ll sit at a console and guide robots to perform the procedure with far greater precision and comfort. Surgeons will be able to do more procedures with better ergonomics. Today, 66% of ophthalmic surgeons suffer from spinal injuries due to physical strain, our platform helps solve that.”
From a patient’s perspective, he added, “They know they’re getting the highest quality care.”
The global vision crisis, affecting over one billion people with preventable vision impairment and avoidable blindness, is exacerbated by a limited and declining ophthalmologist workforce. Worldwide, there are only 31.7 ophthalmologists and 14.1 cataract surgeons per million people. By 2035, the number of practicing ophthalmologists is expected to decline by 12%, while demand for eye care is projected to rise by 24%. Simultaneously, more than 600 million people suffer from cataracts, yet only 30 million receive surgical treatment. In the United States alone, just four million cataract surgeries are performed annually, underscoring the significant gap between patient need and available surgical capacity.
Related articles:
The ORYOM platform is designed to deliver highly precise and consistent ophthalmic procedures, starting with cataract surgery. Leveraging AI-based algorithms, advanced computer vision, and micromechanics, the robotic system offers exceptional dexterity and maneuverability, while also improving the surgeon’s ergonomic experience.
“Cataracts are part of aging, and rates are rising with obesity and diabetes. But many surgeons are retiring, and there’s not enough new talent entering the field,” Nathan noted. “This gap will only grow.”
Dr. Nathan calls the Series B one of the largest medical funding rounds in Israel in recent years, an exceptional feat in a turbulent time.
“We see ophthalmology as the next frontier in medical robotics, just like general surgery was before Intuitive Surgical revolutionized it with the da Vinci system. It’s a massive market with urgent global need.”
The company’s advisory board includes Dr. Fred Moll, the founder of Intuitive Surgical and the da Vinci surgical system, and Mr. Rony Abovitz, the founder of MAKO Surgical Corp. Dr. Fred Moll recently joined the company's board of directors. Additionally, ForSight Robotics benefits from the expertise of a world-class clinical advisory board that includes Dr. David Chang, Dr. Vance Thompson, Prof. Boris Malyugin, Dr. Sam Garg, and Dr. Modi Naftali.
